Diet and lifestyle interventions in active surveillance patients with favorable-risk prostate cancer

被引:12
|
作者
Kenfield S.A. [1 ]
Chang S.T. [1 ]
Chan J.M. [1 ]
机构
[1] University of CA San Francisco, San Francisco, CA 94143-1695
关键词
Prostate Cancer; Genistein; Lycopene; Active Surveillance; Daidzein;
D O I
10.1007/s11864-007-0034-0
中图分类号
学科分类号
摘要
Active Surveillance (AS) is a viable, alternative option for patients who are diagnosed with favorable prognostic risk prostate cancer, and who are willing to undergo conservative, expectant management until treatment is warranted due to progression of the disease. Lifestyle interventions in patients who choose AS is an emerging area of research, and several studies are ongoing with results pending. New intervention studies will increase our knowledge of the etiology of prostate cancer and help determine whether dietary factors can influence prostate carcinogenesis after diagnosis in AS patients. The considerable amount of epidemiologic and experimental data relating components of the diet with prostate cancer risk suggest that diet or lifestyle interventions could potentially lengthen the period of active surveillance before treatment management is necessary, and further research is warranted to study the direct effects on secondary clinical outcomes. © Current Science Inc. 2007.
引用
收藏
页码:173 / 196
页数:23
相关论文
共 50 条
  • [1] Thoughts on Criteria for Active Surveillance of Favorable-risk Prostate Cancer
    Gettman, Matthew T.
    [J]. EUROPEAN UROLOGY, 2016, 70 (06) : 961 - 962
  • [2] Incidence of Reclassification in Patients Undergoing Active Surveillance for Favorable-Risk Prostate Cancer
    Kim, J.
    Davis, J. W.
    Ward, J.
    Wang, X.
    Pettaway, C.
    Pisters, L.
    Matin, S.
    Kuban, D.
    Frank, S. J.
    Lee, A. K.
    Prokhorova, I. N.
    Brown, V. T.
    Logothetis, C. J.
    Troncoso, P.
    [J]. LABORATORY INVESTIGATION, 2011, 91 : 204A - 204A
  • [3] Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review
    Lawrentschuk, Nathan
    Klotz, Laurence
    [J]. KOREAN JOURNAL OF UROLOGY, 2010, 51 (10) : 665 - 670
  • [4] Active surveillance for favorable-risk prostate cancer: who, how and why?
    Klotz, Laurence
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (12): : 692 - 698
  • [5] Active surveillance for favorable-risk prostate cancer: who, how and why?
    Laurence Klotz
    [J]. Nature Clinical Practice Oncology, 2007, 4 : 692 - 698
  • [6] Incidence of Reclassification in Patients Undergoing Active Surveillance for Favorable-Risk Prostate Cancer.
    Kim, J.
    Davis, J. W.
    Ward, J.
    Wang, X.
    Pettaway, C.
    Pisters, L.
    Matin, S.
    Kuban, D.
    Frank, S. J.
    Lee, A. K.
    Prokhorova, I. N.
    Brown, V. T.
    Logothetis, C. J.
    Troncoso, P.
    [J]. MODERN PATHOLOGY, 2011, 24 : 204A - 204A
  • [7] Active surveillance for favorable-risk prostate cancer: What are the results and how safe is it?
    Laurence Klotz
    [J]. Current Urology Reports, 2007, 8 (5) : 341 - 344
  • [8] ACTIVE SURVEILLANCE FOR FAVORABLE-RISK PROSTATE CANCER: AN UPDATE OF THE UNIVERSITY OF MIAMI PROGRAM
    Soloway, Mark S.
    Eldefrawy, Ahmed
    Manoharan, Murugesan
    Iremashvili, Viacheslav
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E273 - E274
  • [9] Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer
    Thomsen, Frederik B.
    Roder, M. Andreas
    Jakobsen, Henrik
    Langkilde, Niels Christian
    Borre, Michael
    Jakobsen, Erik B.
    Frey, Anders
    Lund, Lars
    Lunden, Dagmar
    Dah, Claus
    Brasso, Klaus
    [J]. CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : E814 - E821
  • [10] Active surveillance versus radical treatment for favorable-risk localized prostate cancer
    Klotz L.
    [J]. Current Treatment Options in Oncology, 2006, 7 (5) : 355 - 362